An observational study in Metastatic Breast Cancer, sponsored by SOLTI Breast Cancer Research Group. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-28.
Sponsored by SOLTI Breast Cancer Research Group · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Breast Neoplasms by SOLTI Breast Cancer Research Group — 4 open to participants now, 9 under way, none of them phase 3. Breast Neoplasms · SOLTI Breast Cancer Research Group.
Among the 29 studies in Breast Neoplasms by SOLTI Breast Cancer Research Group, this one is the only one that started in 2025, is one of 4 observational ones, and was the 28th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →4 of the 29 studies in Breast Neoplasms by SOLTI Breast Cancer Research Group are open now, in 3 countries. Recruiting first, the newest first:
SOLTI Breast Cancer Research Group · Sites in France, Germany, Spain
Ages 18+
SOLTI Breast Cancer Research Group · Sites in Spain
Ages 18+
SOLTI Breast Cancer Research Group · Sites in Spain
Ages 35+ · Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 60 across the 25 interventional studies, 450 across the 4 observational. Of the 20 that completed or were terminated, 2 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
SOLTI Breast Cancer Research Group is the lead sponsor of 32 studies on the registry; 5 are open to participants now.
2 of the studies in Breast Neoplasms by SOLTI Breast Cancer Research Group that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05982093SOLTI Breast Cancer Research GroupElacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer | 2026-12 |
| NCT06991946SOLTI Breast Cancer Research GroupPatient-Centric Study to Assess the Impact of Genomic Profiling on the Treatment of Patients With Metastatic Breast Cancer in Spain | 2027-05-20 |
Add all 2 to your calendar (.ics) → With an account.
Among the 29 studies in Breast Neoplasms by SOLTI Breast Cancer Research Group, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
HOPE Focus is an observational study that aims at promoting research against metastatic breast cancer by means of collective research led by patients (patient-centric trial). Patients with metastatic breast cancer living in Spain will voluntarily register and fulfil their journey in the study through the study's digital tool. Mainly they are prompted to answer questionnaires about their disease and expectations, and to provide a blood sample and an archival tumor biopsy. In HOPE Focus these samples will be genomically analyzed and every patient case will be presented in a multidisciplinary molecular advisory board (MAB). The MAB will issue a plain report explaining the significance of the results and will enumerate future therapeutic options that match patient history and his genomic profile, when feasible. Finally, patients will have to answer short follow-up questionnaires twice a year for 3 years.
The study data will allow us to advance implementing precision medicine to improve the management of current and specially future metastatic breast cancer patients.
HOPE Focus - SOLTI-2401 is a prospective, patient-centered research initiative designed to enhance the treatment of patients with MBC through advanced molecular diagnosis in a real-world clinical setting. It uniquely empowers patients to actively participate in their care, from inclusion and data provision to follow-up, utilizing a web-based digital tool (DT) that streamlines their entire journey within the study. The DT not only facilitates seamless communication between patients and the research team, but also serves as a comprehensive repository for relevant study information.
Patients will lead their own inclusion and participation, providing follow-up data through the DT that will guide them during all their journey in the study. After registration and after undergoing an informative interview, eligible patients will provide electronic signature of the informed consent form, and information about their demographic characteristics and relevant oncological information, all through the DT. In addition, the tool will guide them to attend the closest local partner laboratory to:
The DT will be a reference for patients of the status of their case within the study and will be the main repository of the ICF, clinical information provided by patients, sequencing results and reports generated after Molecular Advisory Board (MAB )discussion. Finally, there will be a three-year active follow-up to capture the impact of molecular diagnosis using the DT.
At the time of disease progression and preferably before the initiation of a new line of therapy, blood will be collected at the closest venue of the partner laboratory. Plasma samples will be tested using a NGS comprehensive panel and a standard genomics report will be generated afterwards.
Participants will be required to provide an archival tumor sample (preferably from a metastatic site) that will undergo genomic characterization. FFPE blocks will be assessed at the study's central laboratory by a pathologist and H\&E slides will be digitalized. Samples with sufficient tumor content will undergo DNA extraction, quantification, and quality control. Valid samples will undergo targeted sequencing using a previously validated capture-based panel including more than 400 genes (mutations, CNA) and biomarkers such as tumor mutational burden (TMB) A standard genomic report will be generated after analysis.
Upon genomic report generation (from blood and/or tissue), a SOLTI dedicated team will present the case at the following Molecular Advisory Board (MAB) meeting. During MAB meetings patient cases will be discussed using the new genomic information and the board will issue a report enumerating the potential future therapeutic strategies to be considered.
MAB reports will be in Spanish and will include a text summarizing the interpretation of results. Reports will be addressed to the participants, but they will also be sent to their oncologists (if participating). In addition to the discussion of the molecular results and the treatment recommendations, the MABs are also intended to generate a platform where the HCPs can learn about emerging strategies in MBC management, how to interpret genomics data and embrace fruitful debates to promote continuous learning. The MAB will be gathering a multidisciplinary group of experts in BC clinical management (including medical oncologists and radiation oncologists), cancer geneticists, experts in bioethics, and pathologists. Besides permanent MAB members, physicians treating study participants will be invited to join their patient's discussion.
One month after MAB report delivery, patients will be required to answer a second questionnaire to capture if the information received was relevant for subsequent treatment decisions.
Importantly, the SOLTI-2401 HOPE-Focus Study will not provide any pharmacological intervention to participants. After MAB report delivery, patients will be treated according to local practice or will be directed to ongoing clinical trials. From this moment, patients will be under active follow-up. Periodically, the DT will require them to fill out brief clinical questionnaires to capture the subsequent treatments received. If patients fail to answer a periodic questionnaire, the study team will contact them to reasonably request for response. This follow-up period will last at least 3 years, as SOLTI has the willingness of maintaining the program if the necessary economic supports are achieved, by extending the follow-up period.
Participation of treating physicians will be highly recommended but not mandatory. Patients will be able to request the involvement of their physicians by providing the physician's name and contact details through the web-based digital tool, in accordance with the Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 (GDPR) and the Organic Law 3/2018 on Protection of Personal Data and Guarantee of Digital Rights (LOPDGDD). Only upon electronic written consent collection they will be involved. Then, they will be able to support patient participation and attend the MAB case discussion.
Obtaining patient-reported experience measures (PREMs) of certain aspects involved in cancer care and in molecular diagnosis (knowledge, expectations, concerns, etc.), will allow the design of future strategies to deliver healthcare respecting individual preferences, needs and values. At inclusion and after receiving the report with the MAB assessment, patients will fill out PREM questionnaires. Moreover, during the follow-up process patients will be inquired about their perception of the study's impact on the treatment decisions taken.
The study will be in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines and applicable regulatory requirements and in accordance with data protection regulations: GDPR and LOPDGDD. Approval of the study protocol will be from an Independent Ethics Committee.
The present initiative intends to build a collaborative patient-centric program for molecular diagnosis in patients with MBC that will facilitate the testing and implementation of novel diagnostic strategies to identify patients who may benefit from precision medicine drugs, either approved or in clinical trials. Moreover, it envisions to promote patient empowerment to live with their disease and to increasing education among HCP and other stakeholders about the potential of molecular diagnosis into MBC care.
Patients diagnosed with metastatic breast cancer living and being treated in Spain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with breast cancer in at least one of these situations:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with metastatic breast cancer of any subtype that have progressed after at least one line of treatment in the metastatic setting
Genetic: Liquid Biopsy · Genetic: Archival Tumor DNA
Patients recently diagnosed with ER+/HER2- metastatic breast cancer as a recurrence during adjuvant treatment and prior to initiating any treatment in the metastatic setting
Genetic: Liquid Biopsy · Genetic: Archival Tumor DNA
Patients with metastatic breast cancer in disease progression will undergo a liquid biopsy
Patients will be prompted to request an archival tumor sample from metastatic origin (preferably) and to send it to the central laboratory for analysis
To evaluate the feasibility of incorporating a molecular diagnosis in the management of patients with metastatic breast cancer following a patient-centric strategy.
Percentage of patients with a valid NGS test and a treatment recommendation by the Molecular Advisory Board.
Time frame: Ongoing basis during 5 years of study duration
To study the clinical impact of genomic testing in terms of matched therapies prescribed by treating physicians
* Percentage of patients who received a matched therapy against an alteration detected by ctDNA and/or tissue targeted sequencing. * Subanalysis based on physician's participation in the study.
Time frame: Ongoing basis during 5 years of study duration
Description of Overall Survival (OS) and Progression Free Survival/Time to Next Treatment (PFS/TTNT) of matched treatments.
* Describe PFS/TTNT with treatments directed to molecular targets identified. * Describe OS from the moment of registration to the death of the patient.
Time frame: Ongoing basis during 5 years of study duration
To study the clinically actionable targets (based on ESCAT) detected using tissue targeted sequencing, and plasma ctDNA targeted sequencing.
Proportion of patients with putatively targetable (ESCAT levels I-II) alterations detected in tissue and plasma ctDNA.
Time frame: Ongoing basis during 5 years of study duration
To study the impact of a liquid biopsy based molecular diagnostic in patients with ER+/HER2- BC whose disease progresses as a recurrence during the adjuvant treatment or as a failure of the 1L of treatment or subsequent in the metastatic setting of patie
* ctDNA detection rate in patients with BC whose disease progresses as a recurrence during the adjuvant treatment or as a failure of the 1L of treatment or subsequent in the metastatic setting of patients from any subtype. * Frequency of mutations identified in ctDNA, distribution of VAFs and the proportion of patients with a targetable mutation in patients with BC whose disease progresses as a recurrence during the adjuvant treatment or as a failure of the 1L of treatment or subsequent in the metastatic setting of patients from any subtype.
Time frame: Ongoing basis during 5 years of study duration
To study the concordance rate for key genomic alterations between ctDNA and tumor targeted sequencing (in a subset of patients who have both samples available).
* Concordance between ctDNA mutation status and tissue mutation status (especially in PI3K-AKT-mTOR pathway genes, ESR1 and HRD and other clinically relevant genes). * Concordance between ctDNA and tissue TMB calculations.
Time frame: Ongoing basis during 5 years of study duration
To describe the genomic landscape of MBC in a real-world population beyond clinical trials using validated targeted sequencing assays in tissue and ctDNA. Frequency of MBC gene mutations in the study population.
Frequency of MBC gene mutations in the study population.
Time frame: Ongoing basis during 5 years of study duration
Plan to share: Undecided
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for May 2027, 24 months after the start.
Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 24 months is below that.
Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
SOLTI Breast Cancer Research Group